News and Press Releases
SGLT2 HYPE – a guideline-relevant, clinical trial aiming to establish SGLT2 inhibitors as a new standard in hypertension therapy, ultimately addressing one of the leading causes of premature mortality in Germany and Europe
25 March 2025 -- Lübeck, Germany -- On January 1, 2025, the European research project SGLT2 HYPE (SGLT2 inhibition for cardiovascular reduction in HYPErtension) was officially launched, receiving €6.99 million...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Clinigen collaborates with Servier to expand access to specialised oncology and haematology medicines in South Africa
17 March 2025 -- London, UK -- Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration...
Category: Drug Delivery, Other, Pharmaceutical
Posted: March 17, 2025
ELRIG Announces Drs Jue Wang and Robert Grundy as Keynote Speakers at Research & Innovation 2025
24 January 2025 -- Cambridge, UK -- The European Laboratory Research & Innovation Group (ELRIG), a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Research...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 24, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Paris voted the ‘heart of pharma’ in Europe
Pharmapack Europe research reveals Île-de-France is the second-best location in Europe for ‘drug manufacturing’ and to ‘start a biotech’ Paris, France – The global drug delivery and packaging industry arrives...
Category:
Posted: January 13, 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS
Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients Mitsubishi Tanabe Pharma Corporation...
Category: BioManufacturing, Drug Discovery
Posted: December 11, 2024
Dewpoint Therapeutics 451 D Street, Suite 104 Boston, MA 02210 USA
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 30, 2024
DRUG DISCOVERY 2024: CONNECTING MINDS, TRANSFORMING SCIENCE, EMPOWERING COMMUNITY
We are proud to be media partners of ELRIG's Drug Discovery 2024! Europe’s largest conference for the drug discovery community returns to London, with scientific tracks covering not only therapeutic...
Category: Drug Discovery
Posted: August 29, 2024
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Cardiac surgery patients treated with XF-73 Nasal gel require significantly fewer post-surgical antibiotics
22 July 2024 – Brighton, United Kingdom – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure...
Category: Biotechnology
Posted: July 22, 2024
Destiny Pharma plc, Sussex Innovation Centre, Science Park Square, Brighton, BN1 9SB UK
Evotec and Pfizer collaborate to advance drug discovery in France
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases 11 July 2024, Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:...
Category: Drug Discovery
Posted: July 11, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...
Category: Drug Discovery
Posted: June 10, 2024
Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK
Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA
Exploring advanced technologies to help bring novel therapies to patients faster Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, predictive design of manufacturing processes and...
Category: Biotechnology, Drug Discovery
Posted: May 16, 2024
Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
How the Birmingham Drug Discovery Hub created an investment-ready ‘drug library’
18 April 2024 -- Birmingham, UK -- A novel approach to drug discovery is enabling University of Birmingham, UK, researchers to overcome the ‘valley of death’, where projects fail due...
Category: Drug Discovery
Posted: April 18, 2024
X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy
2 April 2024 -- Massachusetts, US -- X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr Erin Davis as chief technology officer....
Category: Drug Discovery
Posted: April 2, 2024
